全文获取类型
收费全文 | 263303篇 |
免费 | 24536篇 |
国内免费 | 20577篇 |
专业分类
耳鼻咽喉 | 2011篇 |
儿科学 | 2306篇 |
妇产科学 | 3005篇 |
基础医学 | 32562篇 |
口腔科学 | 4273篇 |
临床医学 | 37861篇 |
内科学 | 38486篇 |
皮肤病学 | 2393篇 |
神经病学 | 14873篇 |
特种医学 | 9543篇 |
外国民族医学 | 198篇 |
外科学 | 25087篇 |
综合类 | 44058篇 |
现状与发展 | 74篇 |
一般理论 | 27篇 |
预防医学 | 15846篇 |
眼科学 | 8172篇 |
药学 | 28189篇 |
299篇 | |
中国医学 | 15570篇 |
肿瘤学 | 23583篇 |
出版年
2024年 | 932篇 |
2023年 | 4373篇 |
2022年 | 11345篇 |
2021年 | 14028篇 |
2020年 | 10639篇 |
2019年 | 9230篇 |
2018年 | 9667篇 |
2017年 | 8510篇 |
2016年 | 8094篇 |
2015年 | 12175篇 |
2014年 | 14951篇 |
2013年 | 12522篇 |
2012年 | 18721篇 |
2011年 | 21528篇 |
2010年 | 13030篇 |
2009年 | 10058篇 |
2008年 | 13330篇 |
2007年 | 13361篇 |
2006年 | 13593篇 |
2005年 | 13851篇 |
2004年 | 8202篇 |
2003年 | 7609篇 |
2002年 | 6375篇 |
2001年 | 5700篇 |
2000年 | 6423篇 |
1999年 | 7179篇 |
1998年 | 4740篇 |
1997年 | 4758篇 |
1996年 | 3678篇 |
1995年 | 3515篇 |
1994年 | 2899篇 |
1993年 | 1965篇 |
1992年 | 2216篇 |
1991年 | 1843篇 |
1990年 | 1570篇 |
1989年 | 1333篇 |
1988年 | 1136篇 |
1987年 | 992篇 |
1986年 | 750篇 |
1985年 | 611篇 |
1984年 | 350篇 |
1983年 | 215篇 |
1982年 | 116篇 |
1981年 | 127篇 |
1980年 | 82篇 |
1979年 | 90篇 |
1978年 | 1篇 |
1975年 | 1篇 |
1965年 | 1篇 |
1962年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 9 毫秒
11.
Jinju Wang Shuzhen Chen Wenfeng Zhang Yanfang Chen Ji C. Bihl 《CNS Neuroscience & Therapeutics》2020,26(12):1255
AimsWe previously showed that the protective effects of endothelial progenitor cells (EPCs)‐released exosomes (EPC‐EXs) on endothelium in diabetes. However, whether EPC‐EXs are protective in diabetic ischemic stroke is unknown. Here, we investigated the effects of EPC‐EXs on diabetic stroke mice and tested whether miR‐126 enriched EPC‐EXs (EPC‐EXsmiR126) have enhanced efficacy.MethodsThe db/db mice subjected to ischemic stroke were intravenously administrated with EPC‐EXs 2 hours after ischemic stroke. The infarct volume, cerebral microvascular density (MVD), cerebral blood flow (CBF), neurological function, angiogenesis and neurogenesis, and levels of cleaved caspase‐3, miR‐126, and VEGFR2 were measured on day 2 and 14.ResultsWe found that (a) injected EPC‐EXs merged with brain endothelial cells, neurons, astrocytes, and microglia in the peri‐infarct area; (b) EPC‐EXsmiR126 were more effective than EPC‐EXs in decreasing infarct size and increasing CBF and MVD, and in promoting angiogenesis and neurogenesis as well as neurological functional recovery; (c) These effects were accompanied with downregulated cleaved caspase‐3 on day 2 and vascular endothelial growth factor receptor 2 (VEGFR2) upregulation till day 14.ConclusionOur results indicate that enrichment of miR126 enhanced the therapeutic efficacy of EPC‐EXs on diabetic ischemic stroke by attenuating acute injury and promoting neurological function recovery. 相似文献
12.
13.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis 下载免费PDF全文
14.
European Archives of Oto-Rhino-Laryngology - Several polymorphisms in a disintegrin and metalloproteinase 33 (ADAM33) have been implicated in susceptibility to allergic rhinitis (AR), but the... 相似文献
15.
我国属胃癌高发国家,且以进展期胃癌为主。以手术和化疗为主的多学科治疗无法有效改善晚期胃癌患者的预后。近年来,免疫检查点抑制剂类药物的疗效在诸多癌症中得到了证实,因此,该类药物在胃癌中的治疗效果也受到了广泛的关注。本文对近年来的相关研究成果进行综述,全面介绍了免疫检查点抑制剂类药物在胃癌治疗中的临床应用情况、联合用药情况以及不良反应。对于其他治疗均失败的晚期胃癌患者,PD-1抑制剂是一个可行的治疗选项,其代表药物派姆单抗是目前唯一被美国食品药品监督管理局批准应用于胃癌治疗的免疫抑制剂类药物,而我国国家食品药品监督管理总局尚未批准任何此类药物应用于胃癌的临床治疗。如何进一步提高治疗的客观缓解率,将会是后续临床和基础研究的一大焦点。 相似文献
16.
17.
Yulong Lian Jing Xiao Chen Zhang Suzhen Guan Fuye Li Hua Ge 《Archives of environmental & occupational health》2016,71(2):74-84
The present study compared the level of occupational strain and work ability among Han, Hui, Uygur, Hui, and Kazakh teachers, and explored ethnic differences based on the associations of psychosocial factors at work, occupational strain, and work ability. A cross-sectional survey was conducted among 2,941 teachers in primary and secondary schools in Xinjiang Province, China. Psychosocial factors, occupational strain, and work ability were measured using the Occupation Stress Inventory—Revised Edition (OSI-R) and Work Ability Index. Han and Hui teachers experienced reduced work ability compared with Uygur and Kazakh teachers, and this finding was caused, in part, by exposure to psychosocial factors at work. The vocational and psychological strains caused by these factors play an important role in reduced work ability among all ethnic teacher groups. The findings indicate the importance of taking action to reduce occupational strain for promoting teachers' work ability in multiethnic workplaces. 相似文献
18.
19.
20.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献